BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220404
DTEND;VALUE=DATE:20220408
DTSTAMP:20260516T012405
CREATED:20211109T090819Z
LAST-MODIFIED:20211109T090819Z
UID:32034-1649030400-1649375999@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy for Muscular Disorders Summit
DESCRIPTION:Mitigating Toxicity & Revolutionizing Muscle Targeting \nThe 2nd Gene Therapy for Muscular Disorders Summit will be returning as an in-person event to Boston in April 2022\, to help gene therapy developers targeting muscular disorders to overcome safety and toxicity \nchallenges and effectively translate their programs into the clinic. \nHighlighting AAV and gene editing challenges for Duchenne’s (DMD)\, Limb-Girdle (LGMD)\, Pompe Disease\, X-Linked Myotubular Myopathy and other muscular disorders\, this industry-focused 4-day event will cover:  \n\nOvercoming immunogenicity challenges and mitigate toxicity with high doses\nOptimizing vector and promoter choice and design for more efficient delivery tomuscle targets\nDefining clinically meaningful muscular endpoints to successfully develop and safely deliver the optimal dose to their muscular targets\n\nJoin over 150 fellow industry experts to learn\, share and benchmark yourselves against your competitors\, and overcome the toxicity and dosage challenges hindering the progress of your gene therapy targeting the muscle. \nTo know more visit: https://ter.li/tbbaua
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-for-muscular-disorders-summit/
LOCATION:Hanson Wade\, Hyatt Regency Boston Downtown\, 1 Ave de Lafayette\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220405
DTEND;VALUE=DATE:20220408
DTSTAMP:20260516T012405
CREATED:20220110T223347Z
LAST-MODIFIED:20220111T091913Z
UID:32756-1649116800-1649375999@www.pharmajournalist.com
SUMMARY:Wet AMD & DME Drug Development Summit
DESCRIPTION:Accelerating the Development of Novel Anti-VEGF\, VEGF-independent Therapies & Drug Delivery Options To Reduce Clinical Burden\, Widen Therapeutic Index & Treatment Options for Non-responders \nThe second edition of the industry-led Wet AMD & DME Drug Development Summit will give comprehensive insight into the current and emerging angiogenesis-\, inflammatory-directed and anti-fibrotic drug development programmes for these three ophthalmic conditions – neovascular age-related macular degeneration (wet AMD)\, diabetic retinopathy (DR) and diabetic macular edema (DME). \nThe 2022 Summit will include interactive presentations and panel discussions\, covering challenging questions for the whole research community such as: \n\nWhat are the future directions for anti-VEGF therapy to increase patient response rates\, prolong treatment durability and reduce clinical burden?\nWhere is the clinical success for targeting VEGF-independent pathways in this multifactorial disease?\nWhat interventions beyond anti-VEGF give treatment options for refractory or not optimally treated patients?\nHow are drug developers using various drug delivery methods – topical\, intravitreal\, suprachoroidal\, port delivery – to expand the therapeutic window?\nHow has optical coherence tomography (OCT) imaging\, including at-home diagnostic testing\, and artificial intelligence-enabled programming personalized wet AMD and DME treatment and supported clinical trials?\n\nAs the only industry-led forum solely dedicated to finding long-lasting therapeutic interventions for wet AMD and DME\, attendees will have the opportunity to review the multiple pathological mechanisms being actively targeted\, identify the latest clinical data from anti-VEGF suppression (antibody fragments\, delivery systems\, bispecific antibodies\, gene therapy)\, combinational approaches\, non- VEGF pathways (integrin and TKI’s) and VEGF-independent (such as targeting plasma kallikrein) therapies. \nMeet the leading ophthalmology drug developers from big pharma\, biotech and academia searching for treatment breakthroughs and actively gathering clinical evidence to demonstrate a favourable benefit/risk ratio for future products to regulators\, clinicians and payers. \nJoin us next April to hear their latest clinical development programs and identify future portfolio strategies for your organisation. \nTo know more visit: https://ter.li/m98rr7
URL:https://www.pharmajournalist.com/event/wet-amd-dme-drug-development-summit/
LOCATION:Embassy Suites by Hilton Boston Logan Airport\, 207 Porter St.\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR